Adaptive Biotechnologies utilizes the adaptive immune system to develop diagnostics and therapeutics, focusing on immune medicine and clinical diagnostics.

Adaptive Biotechnologies

Domain Not Resolving

DNSSEC

Cloudflare CDN

Cloudflare Hosting

Person Schema

Cloudflare

U.S. Server Location

Facebook Sharer

Amazon Virginia Region

reCAPTCHA v2

President, CEO & Co-Founder

Chad Robins

Chief People Officer

Francis Lo

President

Julie Rubinstein

Principal Accounting Officer

Kyle Piskel

Chief Medical Officer

Lance Baldo

Chief Operating Officer

Mark Adams

Chief Commercial Officer

Nitin Sood

Chief Commercial Officer, Immune Medicine

Sharon Benzeno

SVP, General Counsel

Stacy Taylor

Chief Financial Officer

Tycho Peterson

Michelle Griffin

Eric Dobmeier

Matt Kahn

Kevin Conroy

Cassian Yee

Arnold Levine

Edus Warren

Lee Huntsman

Co-Founder, President & CEO

Tom Willis

Senior Vice President & GM, Diagnostic Products

Harlan Robins

Head of Innovation, Co-founder

Chief Business Development Officer

Cristian Ionescu Zanetti

Vice President, Product Management

Ilan Kirsch

Senior Vice President of Translational Medicine

Biotechnology Public Companies With More Than $50M in Revenue

West Coast Companies With More Than 500 Employees

Therapeutics Companies (Top 10K)

Western US Companies With Fewer Than 1000 Employees (Top 10K)

Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.


It was founded in 2009 and headquartered in Seattle, Washington.

OrbiMed

Post-IPO Debt - Adaptive Biotechnologies

ARK Investment Management

Post-IPO Equity - Adaptive Biotechnologies

Secondary Market - Adaptive Biotechnologies

Matrix Capital Management

Series F - Adaptive Biotechnologies

Series E - Adaptive Biotechnologies

Viking Global Investors

Series D - Adaptive Biotechnologies

Series C - Adaptive Biotechnologies

Grant - Adaptive Biotechnologies

Series B - Adaptive Biotechnologies

Computer and Software Services and Scientific Services

Seattle

Washington

United States

North America

Cancer Immunotherapy Global Market 2024 To Reach $175.39Billion By 2028 At Rate Of 12.1%

Cancer Immunotherapy Global Market 2024 To Reach $175.39 Billion By 2028 At Rate Of 12.1%

Adaptive Biotechnologies Gets IVDR Class C Certification for ClonoSeq Assay

Adaptive Biotechnologies Q2 Revenues Drop 12 Percent as MRD Revenues Soar

Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

Cathie Wood's ARK buys ADPT stock, sheds ARKA holdings By Investing.com

Why Adaptive Biotechnologies Topped the Market Today

Earnings call: Adaptive Biotechnologies reports robust MRD growth

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2024 Earnings Call Transcript

An FDA-cleared service for detecting and monitoring minimal residual disease in bone marrow from patients with certain blood cancers.

A tool for profiling and monitoring the adaptive immune response in various diseases, aiding research across multiple disease areas.

A diagnostic test that uses T cell markers to indicate recent or past infection with COVID-19, not cleared or approved by the FDA but authorized for emergency use.

Hungary

Europe

Switzerland

India

Asia

Bangladesh

HTML5

GoDaddy

Modernizr

F5 NGINX

Bootstrap

Wistia

GoDaddy Premium DNS

Google Fonts

DigiCert

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Adaptive Biotechnologies Corporation

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 20, 2024 2:42 PM	044b174f
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 20, 2024 2:42 PM	d8a1f7fc
crunchbase trigger	general	Nov 25, 2024 9:06 AM	cd72255f
crunchbase profile	general	Nov 25, 2024 11:13 AM	9d5d8d3b
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 2:28 PM	9a9095ec
peers	general	Sep 20, 2024 2:42 PM	eda54721
news basic	general	Sep 20, 2024 2:42 PM	5397b6fb
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ADAPTIVEBIOTECH

Adaptive Biotechnologies

Last Close

4.37

22/11 21:00

Market Cap

515.79M

Beta: -

Volume Today

2.30M

Avg: -